© 2023 © 2020 Genprex Inc. All Rights Reserved.
Presentation to Highlight Company’s Gene Therapies for Cancer and Diabetes
Presentation to highlight Genprex’s novel gene therapy pipeline in cancer and diabetes
Presentation to Highlight the Promise of Novel Gene Therapies to Transform Cancer and Diabetes Treatments
Genprex’s President and Chief Executive Officer, Rodney Varner, will be delivering the company’s corporate presentation followed by a Q&A session with participants.
The 2020 Cell and Gene Meeting on the Mesa will be delivered in a virtual format over the course of five days where attendees will be able to watch company presentations on-demand, in addition to two live-streaming panels each day.
Company to provide update on its lead drug candidate, GPX-001 for non-small cell lung cancer, and its preclinical diabetes gene therapy candidate that may have the potential to cure Type 1 and Type 2 diabetes
Mr. Rodney Varner, Chief Executive Officer of Genprex, will deliver an overview of the Company and provide updates on its product pipeline, including the recent Fast Track Designation received from the Food and Drug Administration for its Oncoprex™ immunogene therapy in combination with AstraZeneca’s Tagrisso®.
Genprex’s President and Chief Operating Officer, Julien Pham, MD, MPH, will lead the Company’s presentation and, along with Rodney Varner, the Company’s Chief Executive Officer, will be available for one-on-one investor meetings.
AUSTIN, Texas & CAMBRIDGE, Mass.— (October 9, 2019) — Genprex, Inc.(NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it will be presenting at the inaugural MicroCap Rodeo Investor Conference in Austin, Texas on Tuesday, October 15 at 9:10 a.m.
AUSTIN, Texas & CAMBRIDGE, Mass.— (September 18, 2019) — Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it will present at the Singular Research Midwestern Values Conference on September 19, 2019 via webcast.